Impact of the COVID-19 pandemic on the mental health of the general population and health care workers
Abstract The Health Sciences Foundation has assembled a multi-disciplinary group around a series of questions about the impact of the…
affective and anxiety
Endocannabinoid System and Exogenous Cannabinoids in Depression and Anxiety: A Review
Abstract Background: There is a growing liberalization of cannabis-based preparations for medical and recreational use. In multiple instances, anxiety and…
Cannabinoids to Improve Health-Related Quality of Life in Patients with Neurological or Oncological Disease: A Meta-Analysis
Abstract Background: Cannabinoids have been suggested to alleviate frequently experienced symptoms of reduced mental well-being such as anxiety and depression.…
Determinants of depression and anxiety among type 2 diabetes patients in governments’ hospitals at Harari regional state, Eastern Ethiopia: A multi-center cross-sectional study
Abstract Background: Type 2 diabetes mellitus is the most common health problem globally. Depression and anxiety can exacerbate disease complications,…
Substance Use and Psychological Distress in Mexican Adults during COVID-19 Pandemic: A Cross-Sectional Study
Abstract Objectives: This observational cross-sectional study examined changes in substance use during the coronavirus disease 2019 (COVID-19) pandemic in the…
Regulation of DNA Methylation by Cannabidiol and Its Implications for Psychiatry: New Insights from In Vivo and In Silico Models
Abstract Cannabidiol (CBD) is a non-psychotomimetic compound present in cannabis sativa. Many recent studies have indicated that CBD has a…
Suicidal ideation among Canadian adults during the COVID-19 pandemic: the role of psychosocial factors and substance use behaviours
Abstract Background: Suicide is one of the most important and increasing public health agenda around the world. Since the COVID-19…
Clinical and cognitive improvement following full-spectrum, high-cannabidiol treatment for anxiety: open-label data from a two-stage, phase 2 clinical trial
Abstract Background: Evidence suggests cannabidiol (CBD) has anxiolytic properties, indicating potential for novel treatment strategies. However, few clinical trials of…
Sex-dependent differences in the anxiolytic-like effect of cannabidiol in the elevated plus-maze
Abstract Rationale: Cannabidiol (CBD), the major non-psychoactive constituent of cannabis, has therapeutic potential for the treatment of anxiety. Most preclinical…
Cannabidiol in clinical and preclinical anxiety research. A systematic review into concentration–effect relations using the IB-de-risk tool
Abstract Background: Preclinical research suggests that cannabidiol (CBD) may have therapeutic potential in pathological anxiety. Dosing guidelines to inform future…